Acrivon Therapeutics Common Stock Performance
| ACRV Stock | 1.63 0.05 3.16% |
The firm shows a Beta (market volatility) of 0.89, which signifies possible diversification benefits within a given portfolio. Acrivon Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Acrivon Therapeutics is expected to follow. At this point, Acrivon Therapeutics has a negative expected return of -0.33%. Please make sure to confirm Acrivon Therapeutics' total risk alpha, kurtosis, as well as the relationship between the Kurtosis and market facilitation index , to decide if Acrivon Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Acrivon Therapeutics Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in March 2026. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors. ...more
1 | Disposition of 19904 shares by Blume-jensen Peter of Acrivon Therapeutics, at 2.3 subject to Rule 16b-3 | 11/21/2025 |
2 | 12 Health Care Stocks Moving In Tuesdays Intraday Session | 01/06/2026 |
3 | Acrivon Therapeutics Spotlights ACR368 Endometrial Cancer Data, Adds Serous Arm 3 and FDA Phase 3 Plan | 01/08/2026 |
4 | Acquisition by Blume-jensen Peter of 140540 shares of Acrivon Therapeutics at 5.31 subject to Rule 16b-3 | 01/12/2026 |
5 | Acquisition by Eric Devroe of 10000 shares of Acrivon Therapeutics at 1.7218 subject to Rule 16b-3 | 01/13/2026 |
6 | Acquisition by Levy Adam D. of 8832 shares of Acrivon Therapeutics at 1.6983 subject to Rule 16b-3 | 01/14/2026 |
7 | Disposition of 659 shares by Miller Mary of Acrivon Therapeutics at 1.98 subject to Rule 16b-3 | 01/16/2026 |
8 | Acquisition by Baum Charles M of 20275 shares of Acrivon Therapeutics at 1.2 subject to Rule 16b-3 | 02/06/2026 |
9 | Comparing Innate Pharma and Acrivon Therapeutics | 02/11/2026 |
| Begin Period Cash Flow | 36.4 M | |
| Total Cashflows From Investing Activities | -51.8 M |
Acrivon Therapeutics Relative Risk vs. Return Landscape
If you would invest 238.00 in Acrivon Therapeutics Common on November 17, 2025 and sell it today you would lose (75.00) from holding Acrivon Therapeutics Common or give up 31.51% of portfolio value over 90 days. Acrivon Therapeutics Common is currently does not generate positive expected returns and assumes 7.2413% risk (volatility on return distribution) over the 90 days horizon. In different words, 65% of stocks are less volatile than Acrivon, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Acrivon Therapeutics Target Price Odds to finish over Current Price
The tendency of Acrivon Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 1.63 | 90 days | 1.63 | more than 94.0 |
Based on a normal probability distribution, the odds of Acrivon Therapeutics to move above the current price in 90 days from now is more than 94.0 (This Acrivon Therapeutics Common probability density function shows the probability of Acrivon Stock to fall within a particular range of prices over 90 days) .
Acrivon Therapeutics Price Density |
| Price |
Predictive Modules for Acrivon Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Acrivon Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Acrivon Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Acrivon Therapeutics is not an exception. The market had few large corrections towards the Acrivon Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Acrivon Therapeutics Common, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Acrivon Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.11 | |
β | Beta against Dow Jones | 0.89 | |
σ | Overall volatility | 0.34 | |
Ir | Information ratio | -0.02 |
Acrivon Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Acrivon Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Acrivon Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Acrivon Therapeutics generated a negative expected return over the last 90 days | |
| Acrivon Therapeutics has high historical volatility and very poor performance | |
| Acrivon Therapeutics may become a speculative penny stock | |
| Net Loss for the year was (80.56 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Acrivon Therapeutics generates negative cash flow from operations | |
| Acrivon Therapeutics has a poor financial position based on the latest SEC disclosures | |
| About 58.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: Comparing Innate Pharma and Acrivon Therapeutics |
Acrivon Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Acrivon Stock often depends not only on the future outlook of the current and potential Acrivon Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Acrivon Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 38.3 M | |
| Cash And Short Term Investments | 179.5 M |
Acrivon Therapeutics Fundamentals Growth
Acrivon Stock prices reflect investors' perceptions of the future prospects and financial health of Acrivon Therapeutics, and Acrivon Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Acrivon Stock performance.
| Return On Equity | -0.5 | ||||
| Return On Asset | -0.31 | ||||
| Current Valuation | (74.2 M) | ||||
| Shares Outstanding | 31.56 M | ||||
| Price To Book | 0.40 X | ||||
| EBITDA | (79.55 M) | ||||
| Net Income | (80.56 M) | ||||
| Total Debt | 3.65 M | ||||
| Book Value Per Share | 4.08 X | ||||
| Cash Flow From Operations | (65.67 M) | ||||
| Earnings Per Share | (2.12) X | ||||
| Market Capitalization | 51.43 M | ||||
| Total Asset | 196.59 M | ||||
| Retained Earnings | (196.98 M) | ||||
| Working Capital | 164.41 M | ||||
About Acrivon Therapeutics Performance
Evaluating Acrivon Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Acrivon Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Acrivon Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.37) | (0.39) | |
| Return On Capital Employed | (0.45) | (0.47) | |
| Return On Assets | (0.37) | (0.39) | |
| Return On Equity | (0.52) | (0.50) |
Things to note about Acrivon Therapeutics performance evaluation
Checking the ongoing alerts about Acrivon Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Acrivon Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Acrivon Therapeutics generated a negative expected return over the last 90 days | |
| Acrivon Therapeutics has high historical volatility and very poor performance | |
| Acrivon Therapeutics may become a speculative penny stock | |
| Net Loss for the year was (80.56 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Acrivon Therapeutics generates negative cash flow from operations | |
| Acrivon Therapeutics has a poor financial position based on the latest SEC disclosures | |
| About 58.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: Comparing Innate Pharma and Acrivon Therapeutics |
- Analyzing Acrivon Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Acrivon Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Acrivon Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Acrivon Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Acrivon Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Acrivon Therapeutics' stock. These opinions can provide insight into Acrivon Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Acrivon Stock Analysis
When running Acrivon Therapeutics' price analysis, check to measure Acrivon Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acrivon Therapeutics is operating at the current time. Most of Acrivon Therapeutics' value examination focuses on studying past and present price action to predict the probability of Acrivon Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acrivon Therapeutics' price. Additionally, you may evaluate how the addition of Acrivon Therapeutics to your portfolios can decrease your overall portfolio volatility.